A controlled Trial to evaluate the efficacy and safety of HUATUO ZAIZAO PILLS for the recovery phase of cerebral infarction

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000526

Enrollment

Unknown

Registered

2009-09-08

Start date

2009-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the recovery phase of cerebral infarction

Interventions

Group A:Tablets Acetylsalicylic AcidEntrorosolubilus 100mg, orally taken once daily and HUATUO ZAIZAO PILLS 4g, orally taken twice daily for 6 months . A treating course lasts 6 months.

Group B:Tablets Acetylsalicylic AcidEntrorosolubilus 100mg, orally taken once daily and the mimetics of HUATUO ZAIZAO PILLS 4g, orally taken twice daily for 6 months . A treating course lasts 6 months

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Cerebral infarction according to the diagnosis in Western Medicine; 2. Apoplexy involving the meridians according to the diagnosis in Traditional Chinese Medicine; 3. In the recovery phase of stroke: between 2 weeks and 1 month after the onset; 4. Aged 40 to 75 years old; 5. Able and willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1. patients with cerebral transient ischemic attack(TIA); 2. Apoplexy involving the viscera; 3. patients with cerebral hemorrhage; 4. Pregnant or breast-feeding women; 5. allergic constitution or history of hypersensitivity to HUATUO ZAIZAO PILLS; 6. Apoplexy caused by cerebral tumour, cerebral trauma,and hemopathy, and cerebral embolism caused by rheumatic heart disease, coronary heart disease with atrial fibrillation, confirmed by examinations; 7. Patients with psychotic diseases Patients with serious hepatic, renal, orhematological, Endocrine disease, osteoarthrosis or psychotic diseases; 8. Patients that are taking part in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Changes in neurological deficit score;	—

Secondary

Measure	Time frame
Changes of syndromes of TCM;the incidence of adverse outcomes;Assessment of clinical outcome;recurrence rate;Changes in ability of life score;	—

Countries

China

Contacts

Public ContactZhong Wang

zhonw@vip.sina.com+86 010 64014411

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026